Roivant Sciences Ltd. (ROIV) Insider Trading & SEC Filings

Updated Jul 16, 2026 · Last SEC filing 2026-07-02

Roivant Sciences Ltd. (ROIV) has filed 21 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-07-02. 1 Form 8-K material event filings were reported by ROIV in the last 90 days. 8 Form 144 notices of proposed sale were filed for ROIV stock. InsiderAlpha tracks every ROIV SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About Roivant Sciences Ltd. (ROIV)

SIC classification	Pharmaceutical Preparations (SIC 2834)
SEC CIK	0001635088

90-Day SEC Filing Activity

Form 4 filings (90d)	21
Form 8-K filings (90d)	1
Form 144 notices (90d)	8
Latest Form 4 filing	2026-07-02

Recent ROIV Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2026-06-30	QVT Financial LP	Insider	S — Open-market sale	12.4K	$35.28	$437K	SEC
2026-06-30	Fitzgerald Meghan	Director	S — Open-market sale	10.0K	$34.90	$349K	SEC
2026-06-30	Fitzgerald Meghan	Director	M — Option exercise	10.0K	$8.80	$88K	SEC
2026-06-30	Gline Matthew	CEO	F — Tax withholding / forfeiture	76.2K	$35.39	$2.70M	SEC
2026-06-30	Torti Frank	President and Vant Chair	F — Tax withholding / forfeiture	40.3K	$35.39	$1.43M	SEC
2026-06-30	MANCHESTER KEITH S	Insider	S — Open-market sale	12.4K	$35.28	$437K	SEC
2026-06-30	Sukhatme Mayukh	President & CIO	F — Tax withholding / forfeiture	46.9K	$35.39	$1.66M	SEC
2026-06-30	MANCHESTER KEITH S	Insider	S — Open-market sale	200.0K	$35.45	$7.09M	SEC
2026-06-30	Gold Daniel Allen	Insider	S — Open-market sale	12.4K	$35.28	$437K	SEC
2026-06-29	Epperly Melissa B,	Director	S — Open-market sale	2.7K	$34.71	$95K	SEC
2026-06-29	Epperly Melissa B,	Director	S — Open-market sale	15.0K	$34.32	$515K	SEC
2026-06-29	Gold Daniel Allen	Insider	S — Open-market sale	600.0K	$34.59	$20.75M	SEC
2026-06-29	MANCHESTER KEITH S	Insider	S — Open-market sale	600.0K	$34.59	$20.75M	SEC
2026-06-29	MANCHESTER KEITH S	Insider	S — Open-market sale	200.0K	$34.44	$6.89M	SEC
2026-06-29	QVT Financial LP	Insider	S — Open-market sale	200.0K	$34.44	$6.89M	SEC

All transactions sourced from SEC EDGAR Form 4 filings for Roivant Sciences Ltd. (ROIV). Updated in real time as new filings are submitted to the SEC.

Most-Active ROIV Insiders — Last 90 Days

Insider	Form 4 filings	Total transaction value
Venker Eric	11	$22.03M
Sukhatme Mayukh	7	$39.61M
MANCHESTER KEITH S	6	$56.44M
Epperly Melissa B,	5	$689K
Gold Daniel Allen	5	$49.35M

Recent ROIV Form 8-K Material Events

2026-05-20 — Item 2.02, 9.01 [SEC]
2026-04-02 — Item 2.02, 7.01, 9.01 · Clinical · positive [SEC]
Roivant announced positive topline results from Immunovant's two Phase 3 clinical studies evaluating batoclimab for adults with an autoimmune condition, and initiated a new Phase 2b/3 clinical program for brepocitinib in lichen planopilaris. The company also reported strong cash
2026-03-23 — Item 1.01, 9.01 · Legal · neutral [SEC]
Roivant Sciences (through its subsidiary Genevant Sciences and Arbutus Biopharma) entered into a Settlement Agreement with Moderna on March 3, 2026, to resolve all patent infringement litigation between the parties in the U.S. and internationally. This 8-K/A amendment filing supp
2026-03-03 — Item 1.01, 7.01, 8.01, 9.01 · Legal · positive [SEC]
Roivant Sciences' subsidiary Genevant and Arbutus Biopharma settled patent infringement litigation with Moderna over unauthorized use of lipid nanoparticle (LNP) delivery technology in Moderna's vaccines. Moderna will pay a $950 million noncontingent lump sum payment by July 8, 2
2026-03-03 — Item 7.01, 9.01 · Clinical · positive [SEC]
The FDA has accepted Roivant's New Drug Application (NDA) for brepocitinib for the treatment of dermatomyositis and granted Priority Review status. This is a significant milestone that sets a PDUFA date approximately 6 months away, de-risking the regulatory pathway and bringing t

Recent ROIV Form 144 Notices of Proposed Sale

2026-06-30 — — [SEC]
2026-06-30 — — [SEC]
2026-06-29 — — [SEC]

Form 144 must be filed before insiders sell restricted or control stock above SEC thresholds. A cluster of Form 144 notices often precedes a wave of insider distribution.

Recent Insider Filings

2026-07-02 — Gline Matthew (CEO)
2026-07-02 — Fitzgerald Meghan (Director)
2026-07-02 — Torti Frank (President and Vant Chair)
2026-07-02 — Sukhatme Mayukh (President & CIO)
2026-07-01 — Epperly Melissa B, (Director)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in ROIV insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

ROIV Insider Trading — FAQ

What is the latest insider trade for ROIV?: Roivant Sciences Ltd. (ROIV) had 21 insider filings in the last 90 days, with the most recent on 2026-07-02. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying ROIV stock?: 0 insider purchases of ROIV were filed in the last 90 days.
How many insiders are selling ROIV stock?: 0 insider sales of ROIV were filed in the last 90 days.
Where can I see ROIV SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every ROIV SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Related Companies — Recent Insider Activity

Learn More

Open the live ROIV dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.